EGFR and neoplasm: The ongoing randomized PARERE study (26), investigating rechallenge with panitumumab followed by regorafenib versus the reverse sequence in chemorefractory RAS/BRAF wt patients selected by liquid biopsy, could further clarify the role of anti-EGFR according to primary tumor site.